Print Friendly, PDF & Email

NCT/Study#

NCT03881488 /

CTX-471-001

A Phase 1, Open-Label, Multiple-Ascending Dose Study Of The Safety And Tolerability Of CTX-471 In Patients With Inadequate Responses To PD-1/PD-L1 Checkpoint Inhibitors In Metastatic Or Locally Advanced Malignancies

DISEASE GROUP:
Phase 1 Clinical Trials
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: